Is photosensitivity a common side effect of selective serotonin reuptake inhibitors (SSRIs) such as sertraline, especially after increasing the dose to 125 mg in a patient who has been on sertraline for three months and developed a sunburn‑like rash on sun‑exposed skin?

Photosensitivity on SSRIs: Not Common, But Recognized

Photosensitivity is NOT a common side effect of SSRIs, including sertraline, but it is a recognized and documented adverse reaction that should be considered in your patient who developed a sunburn-like rash on sun-exposed skin after dose escalation to 125 mg.

Evidence from FDA Drug Labeling

The sertraline FDA label explicitly lists photosensitivity among severe cutaneous adverse reactions in post-marketing surveillance, though it does not quantify frequency 1. This places it in the category of rare but serious skin reactions that can occur with sertraline treatment.

Clinical Context and Frequency

Multiple comprehensive SSRI guidelines from 2020 detail extensive adverse effect profiles for SSRIs in children and adolescents, listing common side effects including dry mouth, nausea, diarrhea, headache, diaphoresis, and numerous others—but photosensitivity is notably absent from these detailed adverse effect lists 2. This omission from major clinical practice guidelines strongly suggests photosensitivity is uncommon compared to other SSRI side effects.

Supporting Research Evidence

A 2009 case series documented photoallergic reactions to fluvoxamine and paroxetine, explicitly stating: "Although these drugs are widely prescribed, such photosensitization is rare" 3. The authors noted cross-reactivity between different SSRI molecules and recommended that clinicians and patients be aware of this risk, particularly before phototherapy or prolonged sun exposure.

A 1996 review on photosensitivity with psychotropic medications found that while antipsychotics (particularly chlorpromazine) frequently cause photosensitivity, antidepressants as a class show less consistent photosensitizing potential 4.

Comparison to Other Medications

For context, a 2022 guideline on heart failure management lists antidepressants (including citalopram and clomipramine) among drugs linked to photosensitivity 5, but this is in a comprehensive list that emphasizes drugs like amiodarone (>50% incidence) and thiazide diuretics as the prototypical photosensitizers—not SSRIs.

Clinical Approach to Your Patient

Given your patient's temporal relationship between dose escalation and rash development:

1. Strongly consider sertraline as the culprit, even though photosensitivity is rare with SSRIs
2. Reduce the sertraline dose back to the previous tolerated level (likely 100 mg or lower)
3. Implement strict photoprotection: broad-spectrum sunscreen SPF 30+, protective clothing, avoid midday sun exposure 5
4. Monitor for resolution over 2-4 weeks with dose reduction
5. Consider alternative SSRI if photosensitivity persists, as there may be cross-reactivity between SSRIs 3

Important Caveats

• Rule out other causes of photosensitive eruptions (lupus, porphyria, other medications) 4
• The dose-dependent nature of your patient's reaction (occurring after escalation to 125 mg) is consistent with drug-induced photosensitivity patterns
• Phototesting or photopatch testing can confirm the diagnosis if uncertainty remains 6, 4
• Document this reaction clearly, as the patient should avoid prolonged sun exposure while on any SSRI

The rash presentation (sunburn-like on sun-exposed areas) and timing (after dose increase) are classic for phototoxic drug reactions, making sertraline the likely culprit despite the rarity of this adverse effect with SSRIs.